CASSAVA SCIENCES INC — Investor Relations & Filings
Filings indexed
1,004
across all filing types
Latest filing
2026-05-07
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
SAVA
Cassava Sciences, Inc. is a clinical-stage biotechnology company that develops investigational treatments for Central Nervous System (CNS) disorders. The company's primary focus is on its lead drug candidate, simufilam, a proprietary oral small molecule. Simufilam is designed to modulate the activity of the filamin A (FLNA) protein, which is involved in regulating neuronal development. The development program for simufilam targets conditions such as tuberous sclerosis complex (TSC)-related epilepsy and other mTOR pathway disorders. Preclinical studies in TSC models have shown that simufilam may reduce seizure frequency, supporting plans for future clinical trials.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-05-07 | English | |
| 8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-05-07 | English | |
| 8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-04-28 | English | |
| 8-K - CASSAVA SCIENCES INC (0001069530) (Filer) | 2026-02-19 | English | |
| FORM 8-K | 2025-12-23 | English | |
| FORM 8-K/A | 2025-12-22 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
4 filings
| |||||
| 43596105 | 10-Q - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-05-07 | English | ||
| 42914481 | 8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-05-07 | English | ||
| 38155638 | 8-K - FILANA THERAPEUTICS, INC. (0001069530) (Filer) | 2026-04-28 | English | ||
| 32886944 | 8-K - CASSAVA SCIENCES INC (0001069530) (Filer) | 2026-02-19 | English | ||
|
2025
11 filings
| |||||
| 11109579 | FORM 8-K | 2025-12-23 | English | ||
| 11109585 | FORM 8-K/A | 2025-12-22 | English | ||
| 11109591 | FORM 8-K | 2025-12-18 | English | ||
| 11109619 | FORM 8-K | 2025-12-17 | English | ||
| 11109593 | Regulatory Filings 2025 | 2025-12-08 | English | ||
| 11109595 | 424B2 | 2025-12-05 | English | ||
| 11109620 | FORM 8-K | 2025-12-03 | English | ||
| 11109618 | FORM 4 | 2025-11-25 | English | ||
| 11109599 | FORM 4 | 2025-11-24 | English | ||
| 11109601 | FORM 4 | 2025-11-20 | English | ||
| 11109622 | S-3 | 2025-11-13 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
IMMUTEP LIMITED
Develops LAG-3 targeting immunotherapies for cancer and aut…
|
IMM | AU | Professional, scientific and te… |
|
IMMUTEP Ltd
Biotechnology company developing LAG-3 immunotherapies for …
|
IMMP | US | Professional, scientific and te… |
|
IMPACT BIOMEDICAL INC.
Develops biopharmaceutical products and technologies to pro…
|
IBO | US | Professional, scientific and te… |
|
IMUGENE LIMITED
Clinical-stage immuno-oncology company developing cancer im…
|
IMU | AU | Professional, scientific and te… |
|
IMV Inc.
Pioneering novel immunotherapies using the proprietary DPX®…
|
IMV | CA | Professional, scientific and te… |
|
INBIOGEN CO.,Ltd
A life sciences firm offering bioinformatics and data minin…
|
101140 | KR | Professional, scientific and te… |
|
Incannex Healthcare Inc.
A clinical-stage biopharma firm developing cannabinoid and …
|
IXHL | US | Professional, scientific and te… |
|
Indaptus Therapeutics, Inc.
Develops bacterial-based immunotherapies for cancer and vir…
|
INDP | US | Professional, scientific and te… |
|
InflaRx N.V.
Clinical-stage biopharmaceutical firm developing C5a/C5aR p…
|
IFRX | NL | Professional, scientific and te… |
|
Inhalation Sciences Sweden AB
Develops lab instruments and provides research for preclini…
|
ISAB | SE | Professional, scientific and te… |
CASSAVA SCIENCES INC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33903/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33903 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33903 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33903 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33903}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CASSAVA SCIENCES INC (id: 33903)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.